Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Bardia, A., Tolaney, S. M., Punie, K., Loirat, D., Oliveira, M., Kalinsky, K., Zelnak, A., Aftimos, P., Dalenc, F., Sardesai, S., Hamilton, E., Sharma, P., Recalde, S., Gil, E. C., Traina, T., O’Shaughnessy, J., Cortes, J., Tsai, M., Vahdat, L., … Hurvitz, S. A. (2021). Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals of Oncology, 32(9), 1148–1156. https://doi.org/10.1016/j.annonc.2021.06.002
Authors:
A. Bardia
S.M. Tolaney
K. Punie
D. Loirat
M. Oliveira
K. Kalinsky
A. Zelnak
P. Aftimos
F. Dalenc
S. Sardesai
E. Hamilton
P. Sharma
S. Recalde
E.C. Gil
T. Traina
J. O'Shaughnessy
J. Cortes
M. Tsai
L. Vahdat
V. Diéras
L.A. Carey
H.S. Rugo
D.M. Goldenberg
Q. Hong
M. Olivo
L.M. Itri
S.A. Hurvitz
Affiliated Authors:
K. Kalinsky
Columbia Affiliation:
Author Keywords:
triple-negative breast cancer
trophoblast cell-surface antigen 2
brca
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2021.06.002
PMID:
34116144
DOI:
10.1016/j.annonc.2021.06.002
Journal:
Annals of Oncology
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View Web of Science Record

Record Created: